For millions of Americans living with Major Depressive Disorder (MDD), starting an antidepressant is only the first step on what can become a long and frustrating journey. While antidepressants such as SSRIs and SNRIs help many people recover, approximately one-third of patients fail to achieve remission after their first medication, and many continue to struggle despite trying multiple antidepressants. This is why psychiatrists have emphasized the importance of individualized care and finding unique solutions for all patients.
Key Takeaways
- A group of clinicians conducted a comprehensive meta-analysis to determine how antipsychotic medications can be combined with antidepressants to treat patients with MDD.
- After comparing data from approximately 11,000 patients, the clinicians discovered that the medications that provide the most relief from depressive symptoms do not always correlate with high patient acceptability.
- The results of the study demonstrate that choosing an augmentation therapy path is highly personal; a patient’s experiences, side effects, and preferences vary, and thus it is essential to devise a tailored MDD plan.
- The meta-analysis’ findings are limited due to the fact that no direct head-to-head medication trials took place. Further research into antipsychotics for augmentation therapy is needed.
Importance of Individualized Care for Patients with MDD
When Depression persists despite an adequate antidepressant trial, psychiatrists often recommend augmentation therapy. Among the most commonly prescribed augmentation treatments are atypical antipsychotic medications that have been approved by the FDA specifically for Major Depression.
A new 2026 systematic review and network meta-analysis published in JAMA Psychiatry provides the most comprehensive comparison to date of these medications, helping clinicians and patients better understand how they compare in terms of effectiveness, tolerability, and treatment acceptance.
The findings are important, not only because they clarify differences among these medications, but also because they reinforce a broader message: finding the right treatment for Depression often requires individualized care, and medication is only one part of the treatment landscape.
Why Do So Many People Continue to Struggle With Depression?
Depression is far more complex than a simple chemical imbalance. Brain circuits involved in mood regulation, motivation, cognition, sleep, and emotional processing all contribute to the illness.
Although antidepressants primarily target serotonin and norepinephrine, these neurotransmitters represent only part of Depression’s underlying biology.
Many patients continue experiencing symptoms such as:
- Persistent sadness
- Low motivation
- Fatigue
- Poor concentration
- Excessive rumination
- Feelings of guilt or worthlessness
- Social withdrawal
- Difficulty experiencing pleasure
Even when symptoms improve somewhat, many individuals never achieve full remission. This distinction matters because partial improvement still leaves patients at greater risk for relapse, chronic Depression, impaired functioning, and reduced quality of life.
What Is Augmentation Therapy?
Rather than abandoning an antidepressant that has produced partial improvement, psychiatrists sometimes add a second medication designed to enhance its effects. This process is called augmentation therapy, and several atypical antipsychotics have earned FDA approval as adjunctive treatments for adults with MDD who have not responded adequately to antidepressants alone.
The medications evaluated in the JAMA Psychiatry analysis included aripiprazole, brexpiprazole, cariprazine, lumateperone, and quetiapine extended release (XR). Although originally developed for schizophrenia or bipolar disorder, these medications affect dopamine and serotonin systems in unique ways that can improve depressive symptoms when combined with antidepressants.
The Largest Comparison Yet
Rather than examining a single clinical trial, investigators performed a systematic review and network meta-analysis, one of the highest levels of medical evidence.
The researchers reviewed 22 randomized controlled clinical trials which included nearly 11,000 participants. This information spanned multiple international databases and solely focused on FDA-approved adjunctive antipsychotic treatments. Network meta-analysis allows researchers to compare treatments indirectly, even when head-to-head clinical trials do not exist.
The primary questions were simple: which medication works best? And which medication do patients tolerate best?
Which Medication Was Most Effective?
The investigators ranked medications based on their ability to produce at least a 50% reduction in Depression symptoms.
The hierarchy was:
- Lumateperone
- Aripiprazole
- Brexpiprazole
- Cariprazine
- Quetiapine XR
Lumateperone demonstrated the largest improvement in depressive symptoms, producing the highest response rates and also the greatest likelihood of remission. Researchers also found that lumateperone produced the largest average reduction on the Montgomery-Åsberg Depression Rating Scale (MADRS), one of psychiatry’s most widely used measures of Depression severity.
But Effectiveness Isn’t the Whole Story
The medication that works best isn’t necessarily the medication patients stay on.
One of the study’s most valuable findings involved acceptability, measured by whether patients remained on treatment or discontinued medication for any reason.
The rankings looked very different:
- Aripiprazole
- Cariprazine
- Brexpiprazole
- Quetiapine XR
- Lumateperone
Aripiprazole emerged as the medication patients were most likely to continue taking. Lumateperone, despite having the strongest antidepressant effects, had the highest rate of treatment discontinuation. This illustrates an important clinical principle: the most effective medication is not always the best medication for every individual patient.
Understanding the Balance Between Benefits and Side Effects
Every medication involves weighing potential benefits against possible adverse effects. Interestingly, the study found that lumateperone produced strong antidepressant effects while not being associated with clinically significant weight gain, an important advantage over many psychiatric medications. However, patients receiving lumateperone were more likely to discontinue treatment because of adverse events.
Meanwhile, medications such as aripiprazole appeared somewhat less potent but demonstrated better overall treatment acceptance. These differences highlight the importance of individualized care and treatments rather than based solely on efficacy rankings.
There Is No Universal “Best” Medication
One of the most valuable messages from this research is that Depression treatment should never follow a one-size-fits-all approach.
Psychiatrists consider numerous factors when selecting augmentation therapy, including but not limited to previous medication response, side effects, and drug interactions.
For one patient, avoiding sedation may be the priority. For another, minimizing weight gain may be most important. For someone else, maximizing the chance of remission may outweigh concerns about tolerability. Shared decision-making remains central to good psychiatric care.
Important Limitations of the Study
Although this analysis represents one of the strongest available forms of evidence, the authors emphasize several limitations.
Most importantly, there were no direct head-to-head trials comparing these medications against one another. Network meta-analysis estimates comparative effectiveness statistically rather than through direct comparison.
In addition, nearly all studies were funded by industry, and most lasted only six weeks, limiting long-term maintenance data. The patients’ illness severity and treatment history differed, as did the way that each study defined inadequate antidepressant responses. Given these limitations, rankings should be viewed as helpful guidance rather than absolute truths.
Where Does TMS Fit Into This Picture?
For patients considering augmentation medication, another important question naturally arises: what if adding another medication isn’t the right answer?
Many individuals living with treatment-resistant Depression (TRD) prefer to avoid additional medications because of concerns about side effects, weight gain, sexual dysfunction, sedation, or drug interactions.
Transcranial Magnetic Stimulation (TMS) offers an important alternative.
Unlike augmentation medications, TMS works by directly stimulating underactive brain networks involved in mood regulation using magnetic pulses rather than medication. This treatment is FDA-cleared for TRD, and rather than affecting the entire body, TMS targets the specific brain circuits believed to contribute to Depression.
The Future of Personalized Depression Treatment
While the study did have its limitations, and more research is needed into augmentation medications, clinicians now have better evidence showing meaningful differences in both efficacy and tolerability. The research recognizes the importance of individualized care in psychiatry; it is necessary to promote matching the right therapy to the right patient rather than following a rigid treatment sequence.
This is especially encouraging for those who have not yet found an antidepressant that works for them: there are other options available to support your journey to mental wellness.
Take the Next Step with Mid City TMS
At Mid City TMS, our New York-based treatment center focuses on personalized solutions for every patient. Our practice administers TMS and Spravato treatments, which can be used in addition to other antidepressants to treat MDD and TRD.
If you’re ready to take the next step, please reach out to us online or give us a call at 212-517-1867 to learn more about our services. Depression relief is possible with Mid City TMS.
Sources
- McIntyre, Roger S., et al. “Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.” JAMA Psychiatry, vol. 83, no. 7, 2026, pp. 741–750. doi:10.1001/jamapsychiatry.2026.0658